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The genetic architectures of common, complex diseases are largely uncharacterized. We modeled the genetic architecture underlying genome-wide association study (GWAS) data for rheumatoid arthritis and developed a new method using polygenic risk-score analyses to infer the total liability-scale variance explained by associated GWAS SNPs. Using this method, we estimated that, together, thousands of SNPs from rheumatoid arthritis GWAS explain an additional 20% of disease risk (excluding known associated loci). We further tested this method on datasets for three additional diseases and obtained comparable estimates for celiac disease (43% excluding the major histocompatibility complex), myocardial infarction and coronary artery disease (48%) and type 2 diabetes (49%). Our results are consistent with simulated genetic models in which hundreds of associated loci harbor common causal variants and a smaller number of loci harbor multiple rare causal variants. These analyses suggest that GWAS will continue to be highly productive for the discovery of additional susceptibility loci for common diseases.
GWAS have led to the discovery of many common variants that are associated with complex traits. Given the number of SNPs tested in GWAS, an association must achieve a stringent threshold of statistical significance (P < 5 × 10 −8 ) to be considered validated 1 , and contemporary GWAS are underpowered to achieve this genome-wide significance for SNPs with modest effects on disease risk 2 . Assuming that disease-associated SNPs follow the distribution of effect sizes suggested by the validated associations, it is probable that many more true positive associations reside within GWAS data 3 that have only suggestive statistical evidence of association. Indeed, as sample sizes have increased, many more common variants of modest effect have been discovered for a variety of complex traits [4] [5] [6] [7] . However, validated SNP associations explain only a portion of the liability-scale genetic variance or heritability of disease estimated from classical family studies, leading to the concept of missing heritability 8, 9 . Elucidating the remaining sources of heritability will allow investigators to prioritize resources for future genetic studies, including acquisition of additional samples, technology development for variant discovery and testing (for example, next-generation genotyping arrays or sequencing) and analytical development for detecting associations of causal variants across the allele frequency spectrum.
Recently, two statistical methods were developed to assess the contributions of common SNPs that do not reach genome-wide significance: polygenic analysis 10 and mixed linear modeling 11 . Both methods test many SNPs in aggregate for a collective effect on phenotype. In the first method, an additive polygenic risk score based on SNPs that are below a P value threshold in a discovery GWAS is tested in an independent set of samples. Using this approach, polygenic effects have been shown in schizophrenia 10 , multiple sclerosis 12 , heart rate 13 , height 4 and body mass index 5 . The second method estimates additive genetic variance (heritability) caused by common SNPs using linear mixed-effect modeling including a random effect that represents the polygenic component of trait variation 11, 14 . Applied to height 11 , endometriosis 15 , Parkinson's disease 16 and other complex traits 14, 17 , this method has provided estimates of the heritability caused by common SNPs that are scattered throughout the genome. An additional third method 3 uses power correction based on validated SNP associations to estimate the number of additional SNPs with similar effect sizes, but this method estimates the contribution of more modest associations only by making strong assumptions about the distribution of effect sizes.
Although these methods show that additional variance can be explained by common SNPs in GWAS data, they have not offered meaningful estimates of the number and effect sizes of associated SNPs in the context of a GWAS of a common complex disease. Here, we develop a method integrating polygenic analysis 10 and the simulation of GWAS data under a polygenic disease model, using approximate Bayesian computation, to infer liability-scale additive genetic variance and the numbers, allele frequencies and effect sizes of common SNPs weakly associated with complex disease.
To understand the contribution of common SNPs to the heritability of rheumatoid arthritis, we applied our method to published GWAS data on >28,000 samples from rheumatoid arthritis case-control studies 2, 18 . We compared the results of this analysis with those from Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis a n a ly s i s family based heritability studies, a linear mixed model analysis and a simulation study of common or rare causal variant models. We then extended our analyses to published GWAS data for three additional diseases: celiac disease 19 , myocardial infarction and coronary artery disease (MI/CAD) 20, 21 and type 2 diabetes (T2D) 22 . Our results suggest that in all four of these common diseases, many hundreds of common SNP associations remain to be identified, with total genetic contributions accounting for the majority of the heritability of disease. Our results further suggest that common causal variants of weak effect underlie the vast majority of these genetic contributions.
RESULTS

Polygenic risk scores for rheumatoid arthritis
We used rheumatoid arthritis GWAS data from six independent casecontrol collections including a total of 5,485 seropositive individuals with rheumatoid arthritis (cases) and 22,609 individuals without rheumatoid arthritis of European descent ( Table 1) 2, 18 . We imputed the GWAS data genome wide using the HapMap2 European CEU reference panel for a total of over 2.5 million SNPs. We used a study design in which one dataset was used as the 'test' data and the other five datasets were used for 'discovery' so that case-control batch effects, as well as population stratification, would not be consistent across the discovery and test data.
For the polygenic analysis, we first performed a discovery GWAS using logistic regression with five eigenvectors from the principalcomponent analysis as covariates within each dataset and combined the results across the GWAS datasets using an inverse-varianceweighted meta-analysis. We then removed all known rheumatoid arthritis risk loci (Supplementary Table 1 ) to focus on previously unidentified SNP associations and pruned SNPs by their linkage disequilibrium (LD, r 2 < 0.1) (Online Methods), preferentially retaining the SNPs with lower discovery GWAS P values (P GWAS ), to obtain a set of maximally associated independent SNPs with unknown status with respect to disease risk. We selected sets of SNPs reaching nine different P GWAS threshold values (P GWAS < 10 −4 , 10 −3 , 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5), and for each SNP set, we summed the log-oddsweighted risk allele counts for each individual in an independent test dataset using discovery-GWAS-estimated risk alleles and effect sizes. We tested the resulting polygenic risk scores for association with case-control status using logistic regression with gender and five principal component covariates. Polygenic risk scores based on large numbers of SNPs were significantly associated with rheumatoid arthritis case-control status across a range of P GWAS threshold values (Fig. 1) . The most significant score was from SNPs with P GWAS < 0.05 (12,788 SNPs had P = 3 × 10 −9 ). We also analyzed scores based on SNPs with P GWAS in nonoverlapping intervals (for example, 0.001 < P GWAS < 0.01) and found that significant polygenic risk score associations were caused by SNPs with P GWAS ≤ 0.05 (Supplementary Table 2 ). These results were consistent when we used alternative datasets for testing, alternative quality control and LD pruning thresholds, or alternative strategies for removing previously known associations. In addition, cases with non-autoimmune diseases in the Wellcome Trust Case Control Consortium dataset served as the negative controls and did not have significant polygenic risk score associations (Supplementary Fig. 1 ). Finally, we found the polygenic risk score effects to be scattered diffusely throughout the genome; many chromosomes contributed to a significant polygenic risk score (P GWAS < 0.05) signal (Supplementary Table 3) , and, consistent with the results using an independent method in other complex traits 17 , the polygenic risk score effect sizes estimated here were correlated with chromosome size (R 2 = 0.27, P = 0.007). Thus, polygenic risk score associations seemed to be genuinely caused by polygenic effects that are specific to rheumatoid arthritis disease risk.
Polygenic risk scores in other common diseases
We continued testing our method using datasets for three additional diseases. We performed a polygenic analysis on GWAS data for celiac disease 19 , MI/CAD 20 and T2D 22 (Table 1) . Again, we used the samples P GWAS < 0.01 P GWAS < 0.05 P GWAS < 0.01 P GWAS < 0.05 P GWAS < 10 -3 P GWAS < 0.01 P GWAS < 0.05 P GWAS < 10 -3 P GWAS < 0.01 P GWAS < 0.05 npg a n a ly s i s from the UK as test data, as these data had restricted geographic origins relative to the discovery GWAS data and showed little stratification 19, 21 . For celiac disease, we removed the major histocompatibility complex (MHC) region, which has a very strong effect on risk and on complex long-distance LD patterns; we did not remove any other known risk loci.
We used published GWAS data to show that each disease has a strong polygenic signal. As we saw in the rheumatoid arthritis datasets, the polygenic risk scores were highly significantly and specifically associated with all three of these additional common diseases ( Fig. 1 and Supplementary Fig. 1 ). Although known SNPs associated with disease risk may underlie the polygenic risk score associations for the lowest significance threshold, P GWAS < 10 −4 (celiac disease, 96 SNPs, polygenic risk score P = 2 × 10 −16 ; MI/CAD, 82 SNPs, P = 1 × 10 −6 ; T2D, 98 SNPs, P = 1 × 10 −19 ), adding thousands of independent SNPs with the marginally significant P GWAS < 0.1 did not dilute the significance of the polygenic risk score associations (celiac disease, 21,108 SNPs, P = 3 × 10 −16 ; MI/CAD, 22,723 SNPs, P = 3 × 10 −10 ; T2D, 20,297 SNPs, P = 7 × 10 −20 ).
Disease-associated SNPs and total variance explained
Polygenic scores are made up of an unknown number of true-positive SNPs (signal) as well as many unassociated SNPs (noise). To determine how much signal underlies our results, and, specifically, to estimate the number of associated SNPs along with their total variance explained, we conducted Bayesian inference analyses on our polygenic analysis results. Briefly, we analyzed a polygenic disease model in which independent SNPs (N SNPs ) additively contributed a total liability-scale variance explained (V tot ), with additional parameters included for the distributions of risk allele effect sizes and frequencies (Supplementary Fig. 2) . We simulated the discovery GWAS and polygenic analysis for associated and null SNPs and used polygenic risk score logistic regression R 2 values 23 across nonoverlapping SNP sets, including scores stratified by risk-allele frequency (Supplementary Table 2 ), as summary statistics to compare the simulated and observed results. We used approximate Bayesian computation with rejection sampling and general linear model post-sampling adjustment (ABC-GLM) 24, 25 to estimate the posterior densities of polygenic disease model parameters given the polygenic analysis results (Supplementary Fig. 3 ). See the Online Methods and the Supplementary Note for details. Figure 2 shows the joint posterior probability densities of the two key polygenic disease model parameters, N SNPs and V tot . These densities are well restricted to within the range of uniform priors for these two parameters (N SNPs , 10-10,000 on a log 10 scale; V tot , 0.01-0.5 for rheumatoid arthritis and 0.01-0.99 for the other diseases). For rheumatoid arthritis, excluding all known risk loci, the posterior density mode provided estimates of 18% (95% credible interval, 11-24%) of the total variance being explained by 2,231 independent disease-associated SNPs (95% credible interval 846-4,608) ( Fig. 2 and Table 2 ). Results were robust to alternative prior distributions of the N SNPs and for the effect size paramater β v , and validation analyses indicated that the parameters were inferred with reasonable bias and precision under a wide range of models (Supplementary Fig. 4) . We also applied the previously developed linear mixed-effects modeling (LMM) method 11, 14, 26 . This complementary approach yielded consistent results for the variance explained by common SNPs (directly comparable to our V tot results; Table 2 ). Given that rheumatoid arthritis recurrence rates for relatives of affected individuals yield estimates of a narrow-sense heritability of about 0. 55 (refs. 27,28) a Family based heritability estimates were taken from previous data for rheumatoid arthritis 27, 28 , celiac disease 18, 30 , MI/CAD 31, 32 and T2D 33, 34 . b We excluded some loci in certain analyses: although the family based heritability estimates are based on the whole genome, the extended MHC region was removed from the common GWAS SNP analyses for rheumatoid arthritis and celiac disease, and validated non-MHC loci were further removed from the polygenic modeling analysis of the rheumatoid arthritis GWAS data. 50% CI, 50% credible interval; s.e., standard error. npg a n a ly s i s roughly 65% of the heritability of rheumatoid arthritis can be accounted for by purely additive effects of common SNPs in the GWAS data that tag causal alleles.
We applied the same polygenic-model inference method to celiac disease, MI/CAD and T2D ( Fig. 2 and Table 2 ). We found substantial total liability-scale variance (V tot ) explained by GWAS SNPs (celiac disease, 0.43, outside of the MHC; MI/CAD, 0.48; T2D, 0.49). For a comparison, validated common SNP associations explain 5% (celiac disease, 27 non-MHC loci), 4% (25 MI/CAD loci) 30 and 10% (44 T2D loci) 31 of the total liability-scale disease variance in these three diseases. Taking into account the uncertainty in both methods, heritabilities caused by common SNPs estimated using LMM 11, 14, 26 were consistent with the V tot values estimated using polygenic modeling and Bayesian inference, with no clear pattern of overestimation seen by using one method compared to the other. Although family based heritability estimates vary widely for these three diseases 19, [32] [33] [34] [35] [36] , the majority of their heritability is explained by common SNPs in GWAS data, without exception ( Table 2) : 83-100% of the heritability for celiac disease (heritability of 0.5-0.87, with 0.35 caused by HLA alleles in the MHC 19, 37 ), 80-100% of the heritability for MI/CAD and 70-100% of the heritability for T2D is explained by common SNPs.
Risk allele frequencies and effect sizes
Our Bayesian analysis generated a posterior distribution of polygenic disease model parameters, which determine the minor allele frequencies (MAFs) and genotypic relative risks (GRRs) of the inferred common SNP associations. We calculated the mean posterior distributions of the MAFs and GRRs of the associated SNPs from 1,000 samples from the joint posterior density (Fig. 3) . We also determined the marginal prior distributions for the MAFs and GRRs that were implied by the model parameters' Bayesian priors ( Supplementary  Fig. 2 ). For all four common diseases, the posterior distribution of the MAFs of the associated SNPs was shifted from that of the prior distribution (all GWAS SNPs after LD pruning) toward the SNPs of more intermediate frequency. The posterior distribution of the GRRs indicates that the effect sizes of most of the disease-associated SNPs ranged from almost 1 to approximately 1.05, with larger GRRs being seen for less common MAFs (1-5%) .
Notably, the number of SNPs with moderate effect sizes (measured by liability-scale variance explained; GRR > 1.05 for SNPs with MAF = 0.5 and GRR > 1.1 for SNPs with MAF = 0.05), and the total variance explained by these SNPs, varied markedly across the four diseases. Substantial numbers of SNPs with moderate effect sizes contributed the majority of the inferred total liability-scale variance explained for celiac disease (981 (95% credible interval 
Modeling causal variants
To assess what causal genetic models could explain our results, we performed simulations with causal variants and the resulting tag-SNP associations. Recent theoretical studies have posited that multiple rare causal variants may result in common SNP associations 38 . Such 'synthetic associations' probably do not account for most of the validated GWAS signals 39 , but the contribution of these associations to weaker undiscovered common SNP associations has not been previously considered. We used 1000 Genomes Project 40 data and HAPGEN software 41 to simulate 10-Mb haplotypes in case-control populations under genetic models with varying numbers and effect sizes of either common (MAF > 5%) or rare (MAF < 1%) causal variants and determined the patterns of association at marker SNPs interrogated in the GWAS data. This approach allowed us to identify causal variant models in which GWAS marker SNPs were consistent npg a n a ly s i s with our polygenic modeling inference in terms of both their number and total variance explained (Supplementary Table 4) , as well as their allele frequency and effect size distributions ( Supplementary  Fig. 5 ). Thus, we could directly address allelic heterogeneity and rare causal variant hypotheses underlying weak, polygenic effects in GWAS data.
Only models with few (1-4) common causal variants per locus and those with many (8-16) rare causal variants per locus resulted in associated GWAS SNPs that were consistent with the Bayesian inference results (Supplementary Table 4 and Supplementary Fig. 5 ). We emphasize that to explain weak undiscovered common SNP associations, causal variants must themselves have weaker effects than have been studied previously, particularly for rare causal variants 10, 38, 39, [42] [43] [44] [45] . For consistent causal variant models, we simulated the number of loci genome wide that yielded our inferred total variance that was explained by the associated marker SNPs and calculated the contribution of the causal variants themselves to heritability (Fig. 4) . Under genetic models with common causal variants, our simulations suggested that many hundreds to thousands of common causal variants spread across hundreds of loci would account for roughly the same proportion of heritability as their GWAS marker SNP tags (Fig. 4) but would not account for all of the disease heritability. In contrast, under models in which the causal variants are rare, only a small number of loci explain all of the common disease heritability; with larger numbers of loci, heritability owing to causal variants quickly exceeds realistic heritability estimates.
DISCUSSION
The biometrical model proposed by R.A. Fisher 46 posited that a large number of additive genetic factors inherited in a Mendelian fashion could account for the familial patterns of complex traits. In 1916, Fisher's model was criticized by Karl Pearson as being "out of the range of experiment by Mendelian methods" 47 . With the advent of GWAS that interrogate millions of common SNPs with high-throughput genotyping arrays and imputation, it is now possible to test Fisher's model of inheritance. In our study, we used polygenic analyses of GWAS data to show that a substantial proportion of SNPs reaching at best suggestive levels of statistical significance contribute to common disease risk when considered in aggregate (Fig. 1) .
Our study extends a previously developed method 10 by performing approximate Bayesian computation (ABC-GLM) to estimate the credible region of polygenic disease model parameters (for example, number of SNPs, effect size and allele frequency) that can account for polygenic risk score associations. Bayesian inference, together with consistent results obtained using the previously developed LMM method 11, 14 , provide convincing evidence that substantial variance in disease liability can be explained by common SNPs captured in contemporary GWAS data ( Table 2) . For rheumatoid arthritis, the hidden heritability is on par with the variance explained by the validated risk loci, such that a total of ~36% of the overall disease liability, or ~65% of the total heritability, can be attributed to the purely additive effects of common SNPs. For celiac disease, MI/CAD and T2D, our results suggest that the true heritabilities are on the high sides of the ranges of the family based estimates and that at least ~70% of the heritability of these diseases is explained by common GWAS SNPs.
Bayesian analyses allow for computation of the posterior distribution of polygenic disease model parameters, which can then be used to address questions relating to the genetic architecture of common disease. Here, in addition to estimating the number of SNPs and their total variance explained (Fig. 2) , we generated the posterior distribution of the allele frequencies and effect sizes of the inferred, riskassociated SNPs (Fig. 3) and investigated plausible causal variant models (Fig. 4) . Other potential applications of this type of analysis include performing power calculations to predict the outcomes of future genetic studies, developing future discovery efforts such as Bayesian and pathway-based GWAS 48, 49 , estimating the accuracy of the risk prediction that is attainable with additional validated or unvalidated risk alleles 50, 51 and developing and testing hypotheses for the polygenic adaptation 52, 53 that has affected the risk of complex disease.
Although our results were qualitatively similar across the four common diseases we studied, the inferences did vary, with rheumatoid arthritis having a lower estimate (0.18) of total liability-scale variance explained (V tot ) by GWAS SNPs than the other three common diseases (which ranged from 0.43 to 0.49). This difference is largely a result of the exclusion of known loci for rheumatoid arthritis (~30 risk loci that together explain ~18% of the phenotypic variance). Furthermore, the inferred distributions of the effect sizes of the associated SNPs (measured on the liability scale, implying larger genotypic relative risks for lower minor allele frequencies) varied markedly across diseases: the ratios of the V tot caused by SNPs with moderate compared to weak liability-scale effect sizes (corresponding to GRR > 1.05 compared to 1.01 < GRR < 1.05 for MAF = 0.5) ranged from roughly three for celiac disease and MI/CAD to roughly one-third for rheumatoid arthritis and T2D. These differences in our estimates between diseases may npg a n a ly s i s have implications for the genetics of these diseases and will be validated and better characterized in future studies. Our simulations incorporating causal variants and GWAS marker SNPs are consistent with results from other recent studies 10, [42] [43] [44] [45] and indicate that common causal alleles with weak effects can explain most of the polygenic signal observed in GWAS data. Unlike previous studies, we examined the impact of causal variant models on multiple weakly associated GWAS SNPs rather than considering only the single most strongly associated SNP. We found that relatively weak causal variant effect sizes (GRR ~ 1.04, 1.1, 1.5 or 3.5 for MAF = 50%, 5%, 1% or 0.1%, respectively) are required to be consistent with the polygenic analysis of GWAS data.
We show that underlying genetic models with either common (MAF > 5%) or rare (MAF < 1%) causal variants can be consistent with the data in terms of the total number of associated GWAS SNPs and the variance explained. However, under rare causal variant models for complex traits, on the order of ten causal loci are required or the variance explained by causal variants will exceed the heritability of disease 38 . This is because rare causal variants result in many weakly associated GWAS SNPs (because they are not well tagged by any single common SNP) with less total variance explained than the amount explained by the causal variants themselves and because substantial allelic heterogeneity (eight or more rare causal variants per locus) is required to induce associations throughout the common SNP frequency spectrum 38, 39, 45 . As our polygenic analysis suggested that the associations are diffuse throughout the genome, we conclude that the majority of the causal variants that underlie the polygenic signal of association in the GWAS data are themselves common and not rare. Common causal variants would account for a proportion of heritability only slightly greater than that of the SNPs associated within GWAS, leaving some heritability still unexplained.
We do not rule out the possibility of a contribution of rare causal variants. Indeed, a genetic model positing a mixture of loci harboring common and/or rare causal variants would fit the posterior distribution of associated GWAS SNPs better than any single model we simulated; this conclusion is based on the observation that the common causal variant models generated slightly fewer low-frequency, moderateeffect-size GWAS alleles compared to our posterior distribution, whereas rare-variant models generated slightly more ( Supplementary  Fig. 5 ). A genetic model that posits a mixture of common and rare causal variants could explain all of the heritability of disease but would still be dominated by common causal variants (Fig. 3) . Finally, we note that many extremely rare causal variants that segregate privately within families would not induce SNP associations within GWAS data and, therefore, could contribute to the remaining estimated heritability under the causal variant models we studied.
Even if a complex disease is highly polygenic, it is probable that risk loci will implicate a limited number of disease-relevant biological pathways. Recent studies have shown that genes in validated rheumatoid arthritis risk loci are functionally related in terms of their descriptions in the literature 29, 54 , their physical interactions 55 and the tissues in which they are specifically expressed 56 . Furthermore, larger sets of suggestive loci show an over-representation of broad functional categories 57 and tissue-specific expression 56 and contribute to the disease associations of canonical molecular biological pathways 49 . By extension, many additional validated risk loci would hold great promise for bioinformatic analyses to be able to point to the mechanisms of common disease pathogenesis.
Our results have major implications for the design of future genetic association studies to identify additional common disease risk loci. Ideally, whole-genome sequencing in large case-control collections would capture all types of variants (SNPs, indels and copy number variants) across the entire range of allele frequencies (common to low frequency to private). However, such a study is prohibitively expensive at this time and comes with its own challenges, both computationally and in the interpretation of the results. The polygenic model posterior distributions for each of the four diseases examined here give expectations of hundreds of SNPs with moderate effect sizes (GRR > 1.05), especially for celiac disease and MI/CAD. Although the contributions of previously validated SNPs must be accounted for in further analyses, the difference between the V tot inferred here and the variance explained by validated SNPs strongly suggests that there exist many associations that would be detectable in larger GWAS. Therefore, our results indicate that the common variant GWAS approach will continue to be a highly productive method of identifying additional risk alleles for common disease.
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